ADB-HEXINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H30N4O2 |
| Molar mass | 358.486 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADB-HEXINACA (also known as ADB-HINACA and ADMB-HEXINACA) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a longer chain homologue of previously encountered synthetic cannabinoid compounds such as ADB-BUTINACA and ADB-PINACA.[1][2] The pharmacology of ADB-HEXINACA and numerous analogues at CB1 and CB2 receptors has been reported.[3]
See also
References
- ^ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (November 2021). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
- ^ Gilbert N, Costello A, Ellison JR, Khan U, Knight M, Linnell MJ, et al. (December 2021). "Synthesis, characterisation, detection and quantification of a novel hexyl-substituted synthetic cannabinoid receptor agonist: (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)" (PDF). Forensic Chemistry. 26: 100354. doi:10.1016/j.forc.2021.100354.
- ^ Sparkes E, Timmerman A, Markham JW, Boyd R, Gordon R, Walker KA, et al. (April 2024). "Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB-HEXINACA". ACS Chemical Neuroscience. 15 (9): 1787–1812. doi:10.1021/acschemneuro.3c00818. PMID 38597712.